The U.S. Food and Drug Administration said on Thursday that Eli Lilly's weight-loss drug shortage has been resolved, ...

Novo Holdings has completed the previously announced acquisition of Catalent in a $16.5bn all-cash transaction. The European ...

That's why Novo Nordisk's shares are worth sticking with for good, and at about $108 apiece, investors can afford two of them ...

Eli Lilly just gave investors several reasons to cheer.

The Food and Drug Administration said Thursday that the longstanding shortage of Eli Lilly’s weight-loss drug Zepbound and ...

After falling off their perch in the last few months of 2024, European healthcare stocks head into a new year facing the ...

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk ( (NVO) ) has provided an announcement.

The big pharma is paying Hansoh $112 million upfront to place its bet on oral GLP-1 receptor agonist HS-1035, with another $1 ...

JAKARTA, INDONESIA - Media OutReach Newswire - 19 December 2024 - Novo Nordisk, AstraZeneca, and Diversey have been ...

NEW DELHI, INDIA - Media OutReach Newswire - 19 December 2024 - Novo Nordisk Global Business Services, phData, Tekwissen, ...